Sangamo Therapeutics Inc (LTS:0R1D)
$ 2.18 -0.06 (-2.68%) Market Cap: 492.41 Mil Enterprise Value: 480.93 Mil PE Ratio: 0 PB Ratio: 12.55 GF Score: 41/100

Sangamo Therapeutics Inc at Jefferies Gene Therapy/Editing Summit Transcript

Oct 08, 2019 / 03:15PM GMT
Release Date Price: $9.53
Maury Raycroft
Jefferies LLC - Analyst

Okay, my name is Maury Raycroft and I am one of the biotech analysts at Jefferies. And I'd like to welcome Sandy Macrae, the CEO of Sangamo Therapeutics. Thanks for joining us today, Sandy.

Sandy Macrae
Sangamo Therapeutics, Inc. - President & CEO

It is a pleasure to be here.

Questions & Answers

Maury Raycroft
Jefferies LLC - Analyst

Great. And so we are going to do a fireside chat. Maybe to start it off, if you can give an overview of Sangamo's pipeline for people that are new to the story, and what are important catalysts for the next 6 to 12 months.

Sandy Macrae
Sangamo Therapeutics, Inc. - President & CEO

So Sangamo is a fascinating Company. We are the genomic medicine company. We are known for our zinc fingers and our editing capabilities and editing is core of what we do. But if you can do editing, you can do a range of different things through our knowledge of genomic manipulation and AAVs and taking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot